This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (21)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Combination of Suppositories of Calcitonin and a Single Infusion of 3-Amino 1-Hydroxypropylidene-1-bisphosphonate

D. Thiébaud, MD; A. F. Jacquet; P. Burckhardt, MD

Arch Intern Med. 1990;150(10):2125-2128.

Abstract
• Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days. To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls. All patients receiving the combination of calcitonin and APD achieved normalization of the plasma calcium level within 9 days, with a decrease from 3.22 ±0.90 mmol/L (mean ± SEM) to 2.29 ± 0.03 mmol/L. In the group receiving APD alone, the plasma calcium level normalized in only 14 of 17 patients by day 9. In the group receiving calcitonin and APD, the drop in the plasma calcium level occurred more rapidly, and the plasma calcium values were lower from days 2 to 4. This advantage was explained by the calciuric effect of calcitonin, as reflected by a significant decrease in the notional setting of renal reabsorption of calcium, reaching 2.16±0.06 mmol/L compared with 2.34 ± 0.06 mmol/L in the group receiving APD alone. There were no side effects of both treatments, in particular neither flushing nor nausea induced by the suppositories of calcitonin. Clinical Improvement occurred after 2 days In the group receiving the combined treatment. In conclusion, the combined treatment is rapidly effective and safe in the treatment of patients with hypercalcemia, particularly when the notional setting of renal tubular reabsorption of calcium Is increased and a rapid correction of the plasma calcium level is needed.

(Arch Intern Med. 1990;150:2125-2128)

Author Affiliations
From the Department of Internal Medicine, University Hospital Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Footnotes
Accepted for publication February 21, 1990.

Reprints not available.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Narrative Review: Furosemide for Hypercalcemia: An Unproven yet Common Practice
LeGrand et al.
ANN INTERN MED 2008;149:259-263.
ABSTRACT | FULL TEXT  

Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone
Clines and Guise
Endocr Relat Cancer 2005;12:549-583.
ABSTRACT | FULL TEXT